(NASDAQ:AFFX) announced today the launch of Concurrent
Molecular Analysis Profiling (CoMAP™) capability , which enables
cancer researchers to gain rapid insight into the functional impact of
DNA copy number alterations by combining whole-genome copy number data
with gene expression profiles to easily and cost-effectively visualize
and identify cancer driver events.
for Affymetrix Launches Solution to Enable Cancer Researchers to Rapidly Map the Functional Impact of DNA Alterations on Gene Expression Profiles to Identify Potential Cancer Driver Events investment picks